Subclinical atrial fibrillation and the risk of heart failure: insights from ARTESiA - PubMed

5 hours ago

Subclinical atrial fibrillation (SCAF) progression to episodes >24 hours or clinical atrial fibrillation significantly increases the risk of heart failure hospitalization or HF-related death.
In the ARTESiA trial, SCAF progression occurred in 31% of patients over a mean follow-up of 4.1 years, with HF events at a rate of 3.3 per 100 person-years overall, and 7.2 per 100 person-years after progression.
SCAF progression was identified as an independent risk factor for HF events, with a hazard ratio of 2.72, while episodes shorter than 24 hours were not associated with increased HF risk.
The findings highlight the importance of close monitoring in SCAF patients to detect progression and potentially improve outcomes through timely intervention.

Hasty Briefsbeta